Mechanical stretch decreases IL-10 receptor and IL-10 gene expression and increases SOCS3. by Michael A. Hokenson (391291)

Decreased PGC-1α expression is associated with a hyperglycemia-induced increase in mitochondrial fragmentation and ROS generation. by Kaifeng Guo (296791)

Results of XCOM and step velocity. by Saori Miyagishima (14593506)

Subjects:

Silencing of MAGE-A expression decreases the levels of MDM4 via the proteasome and increase MDM2/MDM4 association. by Lynnette Marcar (743770)

Nectin-1 staining is decreased in HSV1-infected keratinocytes, but enhanced as a collar in surrounding uninfected cells. by Hafsa Rana (8201886)

Monocolonization with <i>E. coli</i> JP313 decreases TLR6 transcript levels. by Nives Hörmann (661069)

Differentiation of MDSPCs to a neurogenic lineage prior to implantation decreases their ability to respond to environmental cues and stops transformation. by Mitra Lavasani (343357)

IFN-λ1 decreases miR-122 transcription through down regulation of HNF4α. by Fatma Aboulnasr (736868)

“…The precipitated complexes were subjected to SDS-PAGE and Western blotting for HNF4α and PPAR-γ. <b>(E)</b> Quantification of the bands in Fig 5D <b>(F)</b> Schematic representation of putative HNF4α binding sites in human miR-122 gene promoters and the mechanisms for how IFN-λ1 decreases miR-122 transcription through reduced binding of HNF4α to DR1 element, **p≤0.01, ***p≤0.001.…”

Summary of five key points guiding the Safe Steps evaluation and implementation. by Esario IV Daguman (21474116)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Data from: Mistletoe host diversity decreases with elevation in a temperate rainforest of southern Chile: implications for frugivory by Victoria P. Fernández (11989404)

“…<p dir="ltr">Original data from:</p><p dir="ltr">Fontúrbel, F.E., J.I. Orellana, Fernández, V.P., G.C. Amico & R.F. …”

MEK1/2 inhibition promotes invasive-opposing leading edge lamellipodial structures in 3-D by increasing localised Rac1 activity and decreasing localised RhoA activity. by Joseph H. R. Hetmanski (2656735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Comparison of the Th2 cytokine expression level after treatment with KA/E2 in WT and TLR2 KO mice. by Mi-Kyung Park (56053)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)